Financial Perspectives, Inc Zai Lab LTD Transaction History

Financial Perspectives, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Jan 09, 2024	SELL	$27.77 - $64.4 $0 - $0	0 Closed	0 $0
Q4 2021 Jan 09, 2024	SELL	$54.9 - $105.21 $20,532 - $39,348	-374 Closed	0 $0
Q3 2021 Jan 09, 2024	SELL	$105.0 - $178.37 $24,990 - $42,452	-238 Reduced 38.89%	374 $39.4 Million
Q2 2021 Jan 09, 2024	SELL	$125.11 - $180.0 $10.1 Million - $14.6 Million	-81,047 Reduced 99.25%	612 $108 Million
Q1 2021 Jan 09, 2024	BUY	$126.27 - $191.71 $10.3 Million - $15.6 Million	81,421 Added 34210.5%	81,659 $612,000
Q4 2020 Jan 09, 2024	BUY	$81.94 - $135.34 $14,175 - $23,413	173 Added 266.15%	238 $32.2 Million
Q3 2020 Jan 09, 2024	BUY	$73.3 - $89.48 $4,764 - $5,816	65 New	65 $5.41 Million

123

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.55B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Financial Perspectives, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Perspectives, Inc with notifications on news.